Elevated liver enzymes associated with dronedarone for atrial fibrillation

Abstract

A 51-year-old male with documented atrial fibrillation who was taking dronedarone 400 mg twice daily for approximately 3 months returned to the cardiologist for an ablation procedure. Baseline liver enzymes were within normal range prior to starting the medication and increased after the 3 months of therapy. Aspartate aminotransferase increased from 31 IU/L to 98 IU/L, and alanine aminotransferase increased from 21 IU/L to 101 IU/L. Two and a half months after discontinuation of the medication, liver enzymes normalized (aspartate aminotransferase: 30 IU/L and alanine aminotransferase: 25 IU/L). The Food and Drug Administration has now alerted health-care professionals of the potential for liver injury based upon post-marketing surveillance. The chronological course of elevated liver enzymes noted in our patient is suggestive of a dronedarone-induced problem. Clinicians should have a heightened awareness of the potential for liver enzyme elevation and injury with dronedarone and should monitor enzymes periodically, especially within the first 6 months of use.